H1 2024 revenue rose 13.5% to ¥1.66B and net profit grew 16.4% to ¥1.12B, with both core product lines achieving double-digit growth and high margins. R&D investment and capacity expansion support future growth amid a robust medical aesthetics market.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.